BR112014011341A2 - composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona - Google Patents

composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona

Info

Publication number
BR112014011341A2
BR112014011341A2 BR112014011341A BR112014011341A BR112014011341A2 BR 112014011341 A2 BR112014011341 A2 BR 112014011341A2 BR 112014011341 A BR112014011341 A BR 112014011341A BR 112014011341 A BR112014011341 A BR 112014011341A BR 112014011341 A2 BR112014011341 A2 BR 112014011341A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
pregenen
triol
dione derivatives
receptors
Prior art date
Application number
BR112014011341A
Other languages
English (en)
Inventor
Nehme Alissar
L Edelman Jeffrey
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014011341(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014011341A2 publication Critical patent/BR112014011341A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Abstract

abstract the present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (gr) and/or the mineralocorticoid receptors (mr). the invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (gr) and/or the mineralocorticoid receptors (mr). tradução do resumo resumo patente de invenção: "composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona". a presente invenção refere-se a composições farmacêuticas compreendendo derivados de 4-pregenen-11ß-17-21-triol-3,20-diona, e seu uso como farmacêuticos como moduladores dos receptores glicocorticóides (gr) e/ou os receptores mineralocorticóides (mr). a invenção especificamente refere-se ao uso destes compostos e suas composições farmacêuticas para tratar condições oculares associadas com os receptores glicocorticóides (gr) e/ou os receptores mineralocorticóides (mr).
BR112014011341A 2011-11-11 2012-11-09 composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona BR112014011341A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11
PCT/US2012/064296 WO2013071010A1 (en) 2011-11-11 2012-11-09 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES

Publications (1)

Publication Number Publication Date
BR112014011341A2 true BR112014011341A2 (pt) 2017-05-02

Family

ID=47179019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014011341A BR112014011341A2 (pt) 2011-11-11 2012-11-09 composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona
BR112014011333A BR112014011333B1 (pt) 2011-11-11 2012-11-09 composto, composição farmacêutica e uso do composto de fórmula

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014011333A BR112014011333B1 (pt) 2011-11-11 2012-11-09 composto, composição farmacêutica e uso do composto de fórmula

Country Status (24)

Country Link
US (7) US8865691B2 (pt)
EP (2) EP2776040B1 (pt)
JP (2) JP6158201B2 (pt)
KR (2) KR102049615B1 (pt)
CN (2) CN104203247B (pt)
AR (1) AR088846A1 (pt)
AU (3) AU2012335590B2 (pt)
BR (2) BR112014011341A2 (pt)
CA (3) CA2855290C (pt)
CL (2) CL2014001244A1 (pt)
CO (2) CO6970598A2 (pt)
ES (1) ES2806603T3 (pt)
HK (2) HK1200367A1 (pt)
IL (2) IL232534A0 (pt)
IN (2) IN2014CN03903A (pt)
MX (3) MX365859B (pt)
MY (2) MY182222A (pt)
PH (2) PH12014501078B1 (pt)
RU (2) RU2683775C2 (pt)
SG (3) SG10201603766PA (pt)
TW (1) TWI584809B (pt)
UA (2) UA111867C2 (pt)
WO (2) WO2013071010A1 (pt)
ZA (2) ZA201403430B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
SG11201504452WA (en) 2012-12-18 2015-07-30 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
SG10201709987QA (en) * 2013-12-13 2018-01-30 Allergan Inc Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
CA3037176A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (pt) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (pt) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の１７α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
PL203312B1 (pl) * 1999-10-15 2009-09-30 Leo Pharma As Pochodne kwasu fusydowego, ich zastosowanie oraz kompozycja farmaceutyczna je zawierająca
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
BR0313923A (pt) * 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
PL1755616T3 (pl) * 2004-04-08 2014-10-31 Eye Co Pty Ltd Leczenie mineralokortykoidami retinopatii wysiękowej
EP2216026B1 (en) * 2004-07-12 2016-04-20 Allergan, Inc. Ophthalmic compositions and uses for treating ophthalmic conditions
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
ES2399976T3 (es) * 2006-06-01 2013-04-04 Novagali Pharma S.A. Uso de profármacos para la administración intravítrea ocular
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにｃｐｕユニット
CA2710149A1 (en) * 2007-12-21 2009-07-09 John C. Anthes C20-c21 substituted glucocorticoid receptor agonists
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
UA111867C2 (uk) * 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ

Also Published As

Publication number Publication date
CA2991883A1 (en) 2013-05-16
KR20140095548A (ko) 2014-08-01
ZA201403431B (en) 2016-05-25
JP2014533275A (ja) 2014-12-11
CO6970598A2 (es) 2014-06-13
MX363669B (es) 2019-03-29
IN2014CN03919A (pt) 2015-09-04
US20130123226A1 (en) 2013-05-16
KR102049615B1 (ko) 2019-11-28
NZ624920A (en) 2017-06-30
MY182222A (en) 2021-01-18
CA2855929A1 (en) 2013-05-16
WO2013071009A1 (en) 2013-05-16
MX2014005679A (es) 2014-12-10
US20150057258A1 (en) 2015-02-26
IN2014CN03903A (pt) 2015-10-16
CN104185472B (zh) 2017-06-13
US10188667B2 (en) 2019-01-29
CA2855929C (en) 2018-03-27
US20130123223A1 (en) 2013-05-16
US9433631B2 (en) 2016-09-06
JP6216719B2 (ja) 2017-10-18
MX2014005678A (es) 2014-12-10
JP2014533274A (ja) 2014-12-11
MX365859B (es) 2019-06-18
CN104203247A (zh) 2014-12-10
IL232534A0 (en) 2014-06-30
PH12014501078A1 (en) 2014-07-28
AR088846A1 (es) 2014-07-10
RU2014123471A (ru) 2015-12-20
US20190365786A1 (en) 2019-12-05
AU2018200436B2 (en) 2019-10-24
CL2014001243A1 (es) 2014-11-28
TWI584809B (zh) 2017-06-01
AU2018200436A1 (en) 2018-02-08
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
SG10201603766PA (en) 2016-07-28
PH12014501078B1 (en) 2014-07-28
AU2012335590B2 (en) 2017-10-19
MX2019006877A (es) 2019-08-22
EP2776040A1 (en) 2014-09-17
BR112014011333B1 (pt) 2020-04-28
IL232535B (en) 2019-09-26
HK1200367A1 (en) 2015-08-07
MY172227A (en) 2019-11-18
CN104203247B (zh) 2017-06-06
RU2683775C2 (ru) 2019-04-02
CO6970609A2 (es) 2014-06-13
US9717743B2 (en) 2017-08-01
EP2776040B1 (en) 2020-04-22
SG11201402247PA (en) 2014-06-27
CN104185472A (zh) 2014-12-03
US20180147217A1 (en) 2018-05-31
HK1200366A1 (en) 2015-08-07
AU2012335589B2 (en) 2017-08-31
KR20140095549A (ko) 2014-08-01
US10493082B2 (en) 2019-12-03
UA116622C2 (uk) 2018-04-25
RU2014123472A (ru) 2015-12-20
CA2855290A1 (en) 2013-05-16
WO2013071010A1 (en) 2013-05-16
ZA201403430B (en) 2016-05-25
EP2776041A1 (en) 2014-09-17
US20170182062A1 (en) 2017-06-29
PH12014501079B1 (en) 2014-07-28
BR112014011333A2 (pt) 2017-05-02
CL2014001244A1 (es) 2014-11-14
AU2012335590A1 (en) 2014-05-29
IL232535A0 (en) 2014-06-30
US8906892B2 (en) 2014-12-09
US20150005519A1 (en) 2015-01-01
AU2012335589A1 (en) 2014-05-29
UA111867C2 (uk) 2016-06-24
TW201325596A (zh) 2013-07-01
CA2991883C (en) 2020-03-10
US8865691B2 (en) 2014-10-21
PH12014501079A1 (en) 2014-07-28
SG11201402225RA (en) 2014-06-27
ES2806603T3 (es) 2021-02-18
JP6158201B2 (ja) 2017-07-05
CA2855290C (en) 2017-02-28

Similar Documents

Publication Publication Date Title
BR112014011341A2 (pt) composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112014030678A2 (pt) formas cristalinas de um modulador de receptor de androgênio
BR112015022566A2 (pt) composto e composição farmacêutica
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
BR112015027964A2 (pt) Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística
GT201400016A (es) Indazoles
BR112014020826A2 (pt) moduladores e métodos de uso
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
BR112015008480A2 (pt) compostos de benzeno substituído
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112013027096A2 (pt) compostos de benzotiazol e seu uso farmacêutico
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112013026807A2 (pt) derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112012012261A2 (pt) compostos como moduladores de receptor com utilidade terapêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]